Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Importance of Hepcidin in the Etiopathogenesis of Anemia in Inflammatory Bowel Disease

E. Karaskova, D. Pospisilova, M. Velganova-Veghova, M. Geryk, J. Volejnikova, D. Holub, M. Hajduch

. 2021 ; 66 (10) : 3263-3269. [pub] 20201016

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't, Review

E-resources Online Full text

NLK ProQuest Central from 1997-01-01 to 1 year ago
Medline Complete (EBSCOhost) from 2009-07-01 to 1 year ago
Nursing & Allied Health Database (ProQuest) from 1997-01-01 to 1 year ago
Health & Medicine (ProQuest) from 1997-01-01 to 1 year ago
Family Health Database (ProQuest) from 1997-01-01 to 1 year ago

Anemia is the most common extraintestinal systemic complication of inflammatory bowel disease. Iron deficiency anemia and anemia of chronic disease are among the most frequent types. Intestinal iron absorption is controlled by the activity of ferroportin. Cells with high expression of ferroportin include enterocytes, and also macrophages and hepatocytes. Iron homeostasis is controlled by the hepcidin-ferroportin axis. Hepcidin is a central regulator of iron metabolism and can also serve as a marker of systemic inflammation. During systemic inflammatory response, the synthesis of hepcidin increases, and hepcidin binds to ferroportin and inhibits its activity. Thus, iron is not absorbed from the bowel into the circulation and also remains sequestered in macrophages. Conversely, hepcidin synthesis is suppressed during conditions requiring increased iron intake for enhanced erythropoiesis, such as iron deficiency anemia or hypoxia. Here, ferroportin is not blocked, and iron is actively absorbed into the bloodstream and also released from the stores. Production of hepcidin is influenced by the status of total body iron stores, systemic inflammatory activity and erythropoietic activity. Oral iron therapy is limited in inflammatory bowel diseases due to ongoing gastrointestinal inflammation. It is less effective and may worsen the underlying disease. Therefore, the choice between oral and parenteral iron therapy must be made with caution. Oral iron would be ineffective at high hepcidin levels due to concurrent ferroportin blockage. Contrarily, low levels of hepcidin indicate that oral iron therapy should be successful. An understanding of hepcidin can help in understanding the body's reaction to iron depletion during the inflammatory process.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003559
003      
CZ-PrNML
005      
20220127150112.0
007      
ta
008      
220113s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s10620-020-06652-1 $2 doi
035    __
$a (PubMed)33063192
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Karaskova, Eva $u Department of Pediatrics, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, I. P. Pavlova 185/6, Olomouc, 779 00, Czech Republic. eva.karaskova@fnol.cz
245    10
$a Importance of Hepcidin in the Etiopathogenesis of Anemia in Inflammatory Bowel Disease / $c E. Karaskova, D. Pospisilova, M. Velganova-Veghova, M. Geryk, J. Volejnikova, D. Holub, M. Hajduch
520    9_
$a Anemia is the most common extraintestinal systemic complication of inflammatory bowel disease. Iron deficiency anemia and anemia of chronic disease are among the most frequent types. Intestinal iron absorption is controlled by the activity of ferroportin. Cells with high expression of ferroportin include enterocytes, and also macrophages and hepatocytes. Iron homeostasis is controlled by the hepcidin-ferroportin axis. Hepcidin is a central regulator of iron metabolism and can also serve as a marker of systemic inflammation. During systemic inflammatory response, the synthesis of hepcidin increases, and hepcidin binds to ferroportin and inhibits its activity. Thus, iron is not absorbed from the bowel into the circulation and also remains sequestered in macrophages. Conversely, hepcidin synthesis is suppressed during conditions requiring increased iron intake for enhanced erythropoiesis, such as iron deficiency anemia or hypoxia. Here, ferroportin is not blocked, and iron is actively absorbed into the bloodstream and also released from the stores. Production of hepcidin is influenced by the status of total body iron stores, systemic inflammatory activity and erythropoietic activity. Oral iron therapy is limited in inflammatory bowel diseases due to ongoing gastrointestinal inflammation. It is less effective and may worsen the underlying disease. Therefore, the choice between oral and parenteral iron therapy must be made with caution. Oral iron would be ineffective at high hepcidin levels due to concurrent ferroportin blockage. Contrarily, low levels of hepcidin indicate that oral iron therapy should be successful. An understanding of hepcidin can help in understanding the body's reaction to iron depletion during the inflammatory process.
650    _2
$a anemie $x etiologie $x terapie $7 D000740
650    _2
$a proteiny přenášející kationty $x metabolismus $7 D027682
650    _2
$a regulace genové exprese $7 D005786
650    _2
$a hepcidiny $x metabolismus $7 D064451
650    _2
$a lidé $7 D006801
650    _2
$a idiopatické střevní záněty $x komplikace $7 D015212
650    _2
$a železo $x aplikace a dávkování $x metabolismus $7 D007501
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Pospisilova, Dagmar $u Department of Pediatrics, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, I. P. Pavlova 185/6, Olomouc, 779 00, Czech Republic
700    1_
$a Velganova-Veghova, Maria $u Department of Pediatrics, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, I. P. Pavlova 185/6, Olomouc, 779 00, Czech Republic
700    1_
$a Geryk, Milos $u Department of Pediatrics, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, I. P. Pavlova 185/6, Olomouc, 779 00, Czech Republic
700    1_
$a Volejnikova, Jana $u Department of Pediatrics, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, I. P. Pavlova 185/6, Olomouc, 779 00, Czech Republic
700    1_
$a Holub, Dusan $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Hajduch, Marian $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic
773    0_
$w MED00009570 $t Digestive diseases and sciences $x 1573-2568 $g Roč. 66, č. 10 (2021), s. 3263-3269
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33063192 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127150109 $b ABA008
999    __
$a ok $b bmc $g 1751121 $s 1154708
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 66 $c 10 $d 3263-3269 $e 20201016 $i 1573-2568 $m Digestive diseases and sciences $n Dig Dis Sci $x MED00009570
LZP    __
$a Pubmed-20220113

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...